Facebook Twitter LinkedIn

Dr. Cristina Garmendia Mendizábal

Chairwoman

Dr. Garmendia served as Minister for Science and Innovation of Spain from April 2008 to December 2011, leading some of the most groundbreaking reforms ever made in this area, including the Spanish Innovation Strategy and the Law for Science, Technology and Innovation. In 2001, she founded and developed the biotechnology holding Genetrix, with successful private fundraising of €90 million. In 2008 she founded Ysios Capital, the largest Spanish Biotech capital fund.

She also served as President of the Spanish Bioindustry Association (ASEBIO), as Member of the board at the Spanish Confederation of Employers’ Organizations (CEOE), and as member of various scientific or advisory boards. She is currently a member of the Advisory Board at the Productive Transformation Program, led by the government of Colombia and chaired by Colombian president Juan Manuel Santos.

Other mandates

  • Member of the Board of Directors of Ysios Capital Partner, SGECR S.A., Barcelona, Spain
  • Member of the Board of Directors of Pelayo Mutua de Seguros, Madrid, Spain
  • Member of the Board of Directors of Everis Spain, S.L., Madrid, Spain
  • Member of the Board of Directors of Mediaset España Comunicación, S.A., Madrid, Spain
  • Chairwoman of the Board of Directors of Genetrix, S.L., Madrid, Spain
  • Member of the Board of Directors of Corporación Financiera ALBA, Madrid, Spain
  • Sole Administrator of Jaizkibel, S.L., Madrid, Spain
  • Member of the Board of Directors of Science & Innovation Link Office, S.L., Madrid, Spain
  • Member of the Board of Directors of Compañía De Distribución Integral Logista Holdings, S.A., Madrid, Spain
  • Member of the Board of Directors of Satlantis Microsats, S.L., Madrid, Spain

Mr. Joseph M. Fernández

Deputy Chairman

Co-founder of Invitrogen, Inc., (Currently Life Technologies); founder and CEO/Chairman of Active Motif Inc., which specializes in novel tools and platform technologies for genomics-driven cell biology and epigenetic pathway elucidation.

Other mandates

  • Chairman of the Board of Directors of Active Motif Chromeon GmbH, Tegernheim, Germany
  • Member of the Board of Directors of Expedeon Corporation, Cambridge, UK
  • Member of the Board of Directors of Hiram College, Hiram, Ohio, USA

Pilar de la Huerta

Member of the Supervisory Board

Pilar de la Huerta has accumulated an extensive experience in the pharma and biotech sector over the last 20 years. She joined Genetrix group as a CEO in 2010, moving to SYGNIS after the merger done between Xpol, Genetrix subsidiary, and SYGNIS AG in october 2012. From 2006 to 2010, she was a strategic consultant within several companies, such as Viamed Salud Group, where she was responsible for R&D and New Business and was appointed CEO of the two most innovative companies within the Group: Araclon Biotech, SL. and Viamed Technology Investments. Before that, she was CEO at Neuropharma (Noscira, Zeltia Group) and assumed various responsibilities within the Zeltia Group, (the biggest quoted biotech holding in Spain).

Pilar holds a Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.

CEO and Board Member of Antibióticos de Leon (ADL, S.A.)

Peter Llewellyn-Davies

Member of the Supervisory Board

Peter Llewellyn-Davies is a strategic CFO/CBO with an over 25 year track record in financing activities, international M&A deals, company turnarounds, licensing transactions and with particular experience in chemical and healthcare industries. Currently Peter supports small and medium sized companies with his consulting company Accellerate Partners, targeting in particular enterprises who require the support of a strategically orientated CFO but do not need a full time executive to cover this role. Peter is a non-executive Director and chair of the Audit Committee of Shield Therapeutics plc, who in 2016 completed an AIM listing in London.

Peter was CFO/CBO of Medigene AG between 2012 and 2016 and supported the turnaround process by creating an equity story, outlicensing marketed and legacy products and enhancing shareholder value with a new large international investor base.

Prior to that he was CFO of Wilex AG, having orchestrated their IPO in 2006 to fund a later stage pipeline, setting up investor and public relations and concluding subsequent partnering deals and acquisitions. Prior to this, he was Executive Director of Müller Dairy (UK) Ltd and Executive Director Finance at Süd-Chemie AG. Peter read business management, banking, marketing and controlling in London, St. Gallen and Munich, and has a certificate in business studies from the University of London.

Mr. Tim McCarthy

Member of the Supervisory Board

Tim has a 35 year international business career in high growth Healthcare, Biotech and Technology companies and is currently Chairman and Non Executive Director for a number of companies, including Immupharma Plc, Incanthera, Expedeon Holdings and Harvard Healthcare. He is a former CEO and Finance Director of public and private companies, including Alizyme plc, Peptide Therapeutics Group plc. He has co-founded a number of healthcare and biotechnology companies, raising substantial amounts of equity capital and also advised and/or worked at Board level, for a diverse range of companies internationally, in areas such as business strategy, fund raising, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Other mandates

  • Chairman of the Board of Directors of ImmuPharma PLC, London, U.K.
  • Chairman of the Board of Directors of ARK Analytics Solutions Ltd., Cambridge, U.K.
  • Member of the Board of Directors of Spear Therapeutics Ltd., Manchester, U.K.
  • Chairman of the Board of Directors of Dropped Ltd., Cambridge, U.K.
  • Chairman of the Board of Directors of Incanthera Ltd., Manchester, U.K.
  • Chairman of the Board of Directors of Harvard Healthcare Ltd., Liverpool, U.K.
  • Member of the Board of Directors of Wise old owl Ltd., Cambridge, U.K.
  • Member of the Board of Directors of Frangipani Dreams Ltd., Cambridge, U.K.
  • Member of the Board of Directors of Expedeon Holdings Limited, Cambridge, U.K.

Dr. Trevor Jarman

Member of the Supervisory Board

Dr. Trevor Jarman ist ein innovativer Biochemiker, der an der Gründung und Weiterentwicklung verschiedener Unternehmen der Life-Science- wie auch Healthcare-Branche beteiligt war. Er war Mitbegründer und Business Development Director des Unternehmens Alizyme PLC, welches Arzneimittel entwickelt. Darüber hinaus ist er Vorsitzender des Board of Directors der Expedeon Holdings Ltd. seit deren Gründung im Jahre 2003. Er besitzt einen Bachelor of Science (BSc.) sowie einen Doktor für Biochemie der Universität Hull und war anschließend wissenschaftlicher Mitarbeiter an der Chemie-Fakutät des Imperial College, London, UK

Chief Executive Director of Natures Remedies Ltd., Cambridge, U.K.

Other mandates

  • Chairman of the Board of Directors of Expedeon Holdings Limited, Cambridge, U.K.
  • Member of the Board of Directors of Expedeon Ltd., Cambridge, U.K.
  • Member of the Board of Directors of Cambridge Cell Networks Ltd., Cambridge, U.K.
  • Chairman of the Board of Directors of Persavita Ltd., Cambridge, U.K.
  • Member of the Board of Directors of Swangap Flat Management Ltd., Cambridge, U.K.